A New Function for p53 Ubiquitination  by Hirano, Yuko & Ronai, Ze'ev
Hsp90 ATPase activity that acts as a 
late cofactor of the Hsp90 complex 
(Panaretou et al., 2002; Wegele et al., 
2004). Wang et al., (2006) show that 
overexpression of Aha1 markedly 
destabilized ∆F508 CFTR, whereas its 
downregulation significantly improved 
stability, trafficking, and delivery of 
functional ∆F508 CFTR to the plasma 
membrane. Reduction of Aha1 protein 
levels decreased ∆F508 CFTR binding 
to Hsp90 but did not appear to induce 
cellular stress or alter the levels of 
other chaperones. These findings are 
surprising for several reasons. First, 
Aha1 enhances ∆F508 CFTR degra-
dation, whereas it has been shown 
to promote activation of other Hsp90 
clients (Wegele et al., 2004). Second, 
the downregulation of p23 destabi-
lized ∆F508 CFTR despite predictions 
that p23 downregulation should also 
decrease CFTR binding to Hsp90. 
Although several scenarios could be 
envisioned, these data suggest that 
Aha1 blocks CFTR-Hsp90 interac-
tions in a manner very different from 
p23 and that the outcome depends 
on where in the Hsp90 pathway these 
cofactors act. If p23 facilitates client 
transfer from the Hsp70 to the Hsp90 
system as has been proposed, then 
less CFTR would be transferred to 
Hsp90 when p23 levels were reduced. 
In contrast, a reduction in Aha1 might 
induce late release of CFTR from the 
mature Hsp90 complex, perhaps after 
a transport-permissive conformation 
is achieved. One intriguing possibility 
is that decreasing the levels of Aha1 
allows ∆F508 CFTR increased time 
to bypass a proposed kinetic block 
in folding (Qu et al., 1997). A detailed 
understanding of the temporal recruit-
ment of these and other cochaperones 
will be needed in order to determine 
how the balance of Aha1 and Hsp90 
cycling perturbs the folding environ-
ment to favor ∆F508 maturation.
What is clear from these studies is 
that maturation of at least some pro-
teins that are prone to misfolding can 
be enhanced by manipulation of both 
the Hsp70 and Hsp90 chaperone sys-
tems. For the moment, Wang et al., 
(2006) have focused attention on an 
important decision point that likely 
involves the handoff of client proteins 
from Hsp40/70 to the Hsp90 fold-
ing complex. The next challenge will 
be to determine which of the many 
newly implicated components of this 
network can be targeted to promote 
maturation of specific cargos with 
little cost in terms of toxicity to the 
cell. Such a strategy might be used 
in therapies for diseases associated 
with protein misfolding, including 
cystic fibrosis.
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The amount of p53 protein in a cell is normally limited by ubiquitin-dependent degradation. 
In this issue of Cell, Le Cam et al. (2006) reveal that p53 ubiquitination contributes to tran-
scriptional activation rather than protein stability. These results may provide insight into 
how p53 can modulate diverse cellular processes such as growth arrest and apoptosis.The tumor-suppressor protein p53 is 
a key regulator of cell-cycle control, 
apoptosis, and genomic stability. 
Under normal growth conditions, the stability of the p53 protein is tightly 
regulated. At least five ubiquitin 
ligases (E6-AP, Hdm2, Cop1, Pirh2, 
and ARF-BP1) have been shown to Cell 127, Novmediate ubiquitin-dependent pro-
teasomal degradation of p53. Yet 
how these ligases are regulated and 
coordinated is unknown (Brooks and ember 17, 2006 ©2006 Elsevier Inc. 675
Gu, 2006). In this issue, Le 
Cam et al. (2006) describe 
how ubiquitination under 
certain conditions can 
affect the activity, but not 
the stability, of p53. Here, 
ubiquitinated p53 is found 
within the chromatin frac-
tion where it is bound to the 
promoters of genes asso-
ciated with growth arrest 
(such as p21 and cyclin 
G1) but not genes associ-
ated with apoptosis (such 
as Noxa), suggesting that 
p53 ubiquitination contrib-
utes to the selection of its 
transcriptional targets. The 
Le Cam et al. (2006) study 
addresses a longstand-
ing question, namely, the 
mechanism whereby p53 
can selectively activate 
genes associated with 
growth arrest rather than 
cell death.
The ubiquitination of 
p53 described by Le Cam 
et al. (2006) occurs in 
response to stimuli such 
as DNA damage that nor-
mally result in stabilization 
of p53. This ubiquitina-
tion is promoted by the transcription 
factor E4F1, a zinc-finger protein of 
the GLI/Kruppel family implicated 
in regulation of adenoviral genes 
as well as cell proliferation and sur-
vival (Lee et al., 1987). Given that 
E4F1 is a transcription factor with 
DNA-binding specificity, it is likely 
that the heterodimer p53/E4F1 rec-
ognizes select promoters, as shown 
for the promoter of the p21 gene. Le 
Cam et al. (2006) demonstrate that 
E4F1 facilitates p53 ubiquitination 
within the hinge region (amino acids 
319–321), thereby attenuating p53 
acetylation by the histone acetylase 
PCAF on lysine 320, which is associ-
ated with the activation of apoptosis 
genes by p53. Thus, ubiquitination 
that affects the pattern of p53 acety-
lation may be part of the mechanism 
underlying the selectivity of p53 
transcriptional activity. These obser-
vations raise the possibility that p53 
stability and activity are regulated 
by its associated ligases and deu-
biquitinating enzymes, which are 
expected to affect the length and 
topology of this ubiquitination pro-
cess over time (that is, before, dur-
ing, and after transcriptional activa-
tion by p53). Ubiquitination of p53 is 
also expected to mark it for degra-
dation upon completion of its func-
tion as a transcriptional activator, as 
demonstrated for other transcription 
factors including ATF2 and SREBP 
(Fuchs and Ronai, 1999; Punga et al., 
2006). Although the newly ascribed 
role of p53 ubiquitination is consis-
tent with current understanding of 
ubiquitination in transcriptional con-
trol (Collins and Tansey, 2006), there 
are a number of questions that need 
to be addressed. For example, how 
much of the total p53 bound to the 
p21 promoter is ubiquitinated at dif-
ferent phases during the p53-depen-
dent activation of p21 transcription? 
Which ligases contribute to these 
modifications? How does 
heterodimerization impact 
ubiquitination and assem-
bly of p53 on different pro-
moters? Do different p53 
ligases play distinct roles 
during each phase of tran-
scription directed by p53?
One implication of the 
Le Cam et al. (2006) study 
relates to the pathophysi-
ological consequences of 
deregulated E4F1 expres-
sion for p53 activity. Given 
that E4F1 is regulated by 
c-Myc, one can envision 
changes in the amount of 
the p53/E4F1 complex in 
cells where c-Myc is dereg-
ulated. Such changes may 
constitute a mechanism 
for deregulation of p53 
activities in tumors where 
there is no evidence of p53 
mutations.
Le Cam et al. (2006) 
present E4F1 as a new 
type of ubiquitin ligase. 
However, the functional 
domains within E4F1 that 
may be responsible for its 
ligase activity are limited 
to a single IR region that 
is also found in the SUMO ligase 
RanBP2. Thus, it is possible that 
E4F1 promotes p53 ubiquitination 
by recruiting a bona fide E3 ligase 
that associates with the p53/E4F1 
complex. In support of this possibil-
ity, a growing number of p53-related 
ubiquitin ligases have been found to 
be associated with the promoters of 
p53 target genes. For example, E6-
AP is required for transactivation of 
the HPV-E6 gene (Liu et al., 2005). 
Additionally, Mdm2 (the mouse 
homolog of Hdm2) is found within 
the chromatin-bound p21 promoter 
before, but not after, DNA damage 
(White et al., 2006). The latter finding 
raises the possibility that degrada-
tion of p53 by Mdm2 may take place 
at the promoters of p53 target genes. 
Other Mdm2- and p53-associated 
proteins implicated in transcriptional 
regulation of p53 target genes are 
found at such promoters, includ-
ing hnRNP-K and pVHL. hnRNP-K 
figure 1. p53 Ubiquitination at the Promoters of Its Target 
Genes
Accumulating evidence points to the presence of Mdm2 and its as-
sociated proteins on promoters of p53 target genes prior to DNA dam-
age. This raises the possibility that some of p53 may be degraded on 
the promoters to which it is bound (compare bottom panels). Following 
DNA damage, Mdm2 dissociates from p53 and the promoter, enabling 
p53-mediated transcription—prompted by ubiquitination of p53 in the 
presence of E4F1—to proceed (Le Cam et al., 2006). As other ligases 
(such as pVHL) are present within this complex, transcription controlled 
by p53 ubiquitination may be mediated by several associated ligases. 
This model also stipulates that different promoters may be subject to 
different types of regulation, dictated by the recruitment of different p53 
ligases and associated transcription factors.676 Cell 127, November 17, 2006 ©2006 Elsevier Inc.
is found on the promoters of p53-
responsive genes and is targeted by 
Mdm2 for degradation before, but 
not after, DNA damage (Moumen et 
al., 2005). pVHL—implicated in regu-
lation of HIF1α—was recently shown 
to attenuate ubiquitination of p53 by 
Mdm2 while inducing the interac-
tion between p53 and the acetylase 
p300/CBP that results in increased 
p53 acetylation and transcriptional 
activities (Roe et al., 2006). Thus, 
one may envision that changes in the 
p53 complex before and after DNA 
damage may switch the ligases that 
subject p53 to different modes of 
ubiquitination. Along these lines, one 
wonders how much of p53 degrada-
tion prior to DNA damage is occur-
ring at the promoter sites (compare 
left and right panels in Figure 1) and 
whether different promoters are 
occupied by distinct p53 ligases, 
as well as specific p53 heterodi-
meric partners. Additional post-
translational modifications, includ-
ing acetylation and sumoylation, are 
expected to affect p53 localization 
and its assembly on promoters of its 
target genes.
Although E4F1 is shown by Le 
Cam et al. (2006) to affect activa-
tion of the p21 promoter, it is likely 
that selectivity is acquired by the 
heterodimeric complex of transcrip-tion factors rather than the actual 
ubiquitination per se. Thus, one 
may expect a plethora of transcrip-
tion factors and ubiquitin ligases to 
engage p53 activities on target gene 
promoters that elicit each of p53’s 
distinct functions. 
This is the first report to link p53 
ubiquitination with transcriptional 
activation. However recent stud-
ies have shown that p53 ubiqui-
tination affects its localization and, 
consequently, its activity. WWP1, a 
HECT-domain ligase, causes p53 
ubiquitination but limits its tran-
scriptional activation by exporting 
p53 to the cytosol (Laine and Ronai, 
2006). Ubc13, a ubiquitin-conjugat-
ing enzyme involved in noncanonical 
ubiquitination, was shown to recruit 
p53 to polysomes and prevent p53 
from forming a tetramer, thereby 
affecting its localization and tran-
scriptional activity (Laine et al., 2006). 
One expects that more ligases will be 
found to affect the diverse functions of 
p53 activities by contributing to each 
of the steps required for p53 availabil-
ity, localization, and selective activity. 
Given that most p53 studies have not 
been confined to chromatin-bound 
material, further analysis of p53 within 
this fraction may help to clarify key 
mechanisms engaged in the regula-
tion of p53 availability and activity.Cell 127, NovRefeRences
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